Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140
April 04, 2017 13:00 ET
|
Cyclacel
- Preclinical Data Presented at the AACR 2017 Meeting - BERKELEY HEIGHTS, N.J., April 04, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the...
Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways
April 02, 2017 13:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., April 02, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), today announced the presentation by independent...